Why the study?
Does intravenous magnesium chloride reduce the incidence of supraventricular arrhythmias in patients undergoing elective myocardial revascularisation?
Does intravenous magnesium chloride reduce the incidence of supraventricular arrhythmias in patients undergoing elective myocardial revascularisation?
Intravenous magnesium supplementation during the first 48 hours after elective myocardial revascularization significantly reduces the incidence of postoperative supraventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports perioperative IV magnesium after elective revascularization; confirms benefit for supraventricular arrhythmia prevention in this RCT.
One hundred and thirty patients undergoing elective myocardial revascularisation were randomised to receive an intravenous infusion containing either 50 mmol magnesium chloride or placebo during the first 48 h following surgery. Magnesium was given to 66 patients and a placebo infusion to 64 patients. Postoperative serum magnesium concentrations fell in the placebo group (from 0.83 +/- 0.06 to 0.79 +/- 0.11 mmol/l) but were elevated in the magnesium group (from 0.82 +/- 0.05 to 1.2 +/- 0.25 mmol/l). In total, 35 patients (26.9%) had a supraventricular arrhythmia, of which 11 were in the magnesium group (16.7%) and 24 (37.5%) in the placebo group (P = 0.013). Three patients in the magnesium group had an episode of ventricular fibrillation and three patients in the placebo group had frequent ventricular ectopics. There was one death in the magnesium group associated with a perioperative myocardial infarction. This study shows that intravenous magnesium supplements reduce the incidence of supraventricular arrhythmias following coronary artery surgery.
No takes yet. Share an insight, caveat, or question.
Colquhoun et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: